^
    Back
    Association details:
    Biomarker:PIK3CA E545A
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

    Published date:
    03/13/2020
    Excerpt:
    Likewise, the mutation p.E545A was detected at disease progression in three patients...Table 2 Molecular alterations detected in ctDNA upon progression to osimertinib treatment.
    DOI:
    10.21037/tlcr.2020.04.01